Mometasone furoate nasal spray for nasal polyposis

Abstract

Nasal polyposis occurs in 2–4% of the general population and is associated with significant socioeconomic costs due to severe nasal/airway symptoms that impair quality of life. Nasal corticosteroids are the first-line therapy for nasal polyposis. Mometasone furoate nasal spray is effective in relieving nasal symptoms, including nasal congestion and loss of sense of smell. This is the only intranasal corticosteroid spray to be approved in the USA for the medical treatment of nasal polyposis and the only once-daily corticosteroid spray approved for the treatment of nasal polyposis in the EU. Clinical trials have shown that mometasone furoate nasal spray has a favorable safety profile with no clinically relevant interactions with other tested medications.

Keywords::

• intranasal corticosteroid
• mometasone furoate
• nasal congestion
• nasal polyp
• nasal polyposis

Financial & competing interests disclosure

Pär Stjärne was the principal investigator in Schering-Plough sponsored multicenter clinical trials on intranasal mometasone furoate in the treatment of nasal polyposis.

Writing of this review was supported by Cecilia Falkenberg, TFS Trial Form Support, Sweden and Schering-Plough AB, Sweden.